Stanley Druckenmiller's NAMS Position Overview
Stanley Druckenmiller (via Duquesne Family Office LLC) currently holds 3.07 M shares of NewAmsterdam Pharma Company N.V. (NAMS) worth $98.28 M, representing 2.91% of the portfolio. First purchased in 2024-Q3, this short-term holding has been held for 7 quarters.
Based on 13F filings, Stanley Druckenmiller has maintained this position in NAMS for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 1.15 M shares.
Analysis based on 13F filings available since 2013 Q2
Stanley Druckenmiller's NewAmsterdam Pharma Company NV (NAMS) Holding Value Over Time
Track share changes against reported price movement
Quarterly NewAmsterdam Pharma Company NV (NAMS) Trades by Stanley Druckenmiller
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +1.15 M | Add 59.60% | 3.07 M | $35.08 |
| Q3 2025 | +1.09 M | Add 131.17% | 1.92 M | $28.44 |
| Q2 2025 | +31,815 | Add 3.98% | 832,175 | $18.11 |
| Q1 2025 | +512,825 | Add 178.35% | 800,360 | $20.47 |
| Q3 2024 | +287,535 | New Buy | 287,535 | $16.60 |
Stanley Druckenmiller's NewAmsterdam Pharma Company NV Investment FAQs
Stanley Druckenmiller first purchased NewAmsterdam Pharma Company N.V. (NAMS) in Q3 2024, acquiring 287,535 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Stanley Druckenmiller has held NewAmsterdam Pharma Company N.V. (NAMS) for 7 quarters since Q3 2024.
Stanley Druckenmiller's largest addition to NewAmsterdam Pharma Company N.V. (NAMS) was in Q4 2025, adding 3,070,146 shares worth $107.7 M.
According to the latest 13F filing for Q1 2026, Stanley Druckenmiller's firm, Duquesne Family Office LLC, owns 3,070,146 shares of NewAmsterdam Pharma Company N.V. (NAMS), valued at approximately $98.28 M.
As of the Q1 2026 filing, NewAmsterdam Pharma Company N.V. (NAMS) represents approximately 2.91% of Stanley Druckenmiller's publicly disclosed stock portfolio, making it one of their key holdings.
Stanley Druckenmiller's peak holding in NewAmsterdam Pharma Company N.V. (NAMS) was 3,070,146 shares, as reported at the end of Q4 2025.